Transgene SA (OTCMKTS:TRGNF – Get Free Report) shares dropped 46.2% during trading on Tuesday . The stock traded as low as $0.70 and last traded at $0.70. Approximately 425 shares traded hands during trading, a decline of 2% from the average daily volume of 433 shares. The stock had previously closed at $1.30.
Transgene Stock Performance
The company has a 50-day moving average of $1.57 and a 200 day moving average of $1.58.
About Transgene
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors.
Read More
- Five stocks we like better than Transgene
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- Golden Cross Stocks: Pattern, Examples and Charts
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for Transgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgene and related companies with MarketBeat.com's FREE daily email newsletter.
